TopicKimi K3.1 Pro
Moonshot Pivots Kimi to Science: Biology, Chemistry and Pharma
Moonshot’s international director said at Web Summit in Lisbon on Nov 16 that Kimi models are pivoting from coding to biology, chemistry and pharmaceutical research, as gains on coding benchmarks flatten.

What happened
Giacomo Ficari, Moonshot AI’s international director, said at Web Summit in Lisbon that the company is redirecting its Kimi language models from coding toward biology, chemistry and pharmaceutical research. He said science demands smarter AI models than law, finance or code, and that progress in coding is flattening.
The deployment case: Beijing-based DP Technology is integrating Kimi K3.1 Pro into its research assistant BioMaster. In one test, the system analyzed gene data from 3,696 mouse pancreatic cells and flagged 100 candidate genes in 90 minutes, against an estimated four hours of human work.
The limits: fully independent scientific breakthroughs are still a long way off. On TCSExam, a 100-problem theoretical computer science benchmark, leading models produced verifiable proofs but solved no open conjectures on their own. Anthropic’s Claude found an enzyme system in September, while mathematicians criticized OpenAI’s claimed math and physics breakthroughs; a June Citi survey of 50 US research leaders found 72 percent already using AI broadly, but only 24 percent expected it to noticeably improve drug development success rates.
Key facts
- Pivot: Kimi models move from coding to biology, chemistry and pharmaceutical research, per Ficari at Web Summit in Lisbon
- Reason: Gains on coding benchmarks are flattening; science demands smarter models than law, finance or code
- Case: DP Technology’s BioMaster integrates Kimi K3.1 Pro; gene data from 3,696 mouse pancreatic cells, 100 candidate genes flagged in 90 minutes versus an estimated four hours by hand
- Limits: On the 100-problem TCSExam benchmark, models produced verifiable proofs but solved no open conjectures alone
- Industry: A June Citi survey of 50 US research leaders: 72% use AI broadly, 24% expect it to noticeably improve drug development success rates
Why it matters
Kimi’s focus moves from coding to scientific research, with DP Technology’s BioMaster as a public deployment; the 90-minutes-versus-four-hours comparison comes from a partner test, and independent scientific discovery remains out of reach.
CompaniesMoonshot AI
Grab todayOpenAI Codex for Students: $100 in Free CreditsHIMIAO Picks →Follow HIMIAO Horizon
No sign-up · Unsubscribe any timeNotifications
A ping on your phone or computer when the brief is out. No email needed.
Comments
Related
- Nov 9Kimi K3.1 Pro Review: 2.8T Open Weights, Near-Flagship Terminal Coding, Lagging Science Tasks
- Nov 12Kimi K3.1 Pro vs Qwen3.8-Max: Same $2 Input, $4 Apart on Output
- Nov 5Moonshot Releases Full Kimi K3.1 Pro Weights: 2.8T Parameters, About 1.56 TB
- Oct 24Moonshot Releases Kimi K3.1 Pro: 3-Trillion-Parameter-Class Open-Weight Model, Deliberately Curbed Cyber Capabilities
- Nov 17OpenAI Launches Science Blog as GPT-6 Astra Leads Proof of Candidate Lattice Standard Model Definition
Today
Nov 17 Tuesday- Brief
- GitHubGitHub Weekly Vol.6: 7 Projects Worth a Look This Week
Tested or read — weeklyAll →
- Quiz
- Call
Latest news
All →- Nov 17OpenAI Launches CSAM Image Classifier With 24-Hour ChatGPT Suspensions
- Nov 17Google: Fully Automated AI Cyberattacks Have Arrived
- Nov 17US Commerce Department Names 33 AI Export Packages, AMD Leads 11
- Nov 17US Commerce Department Closes "Cloud Loophole" for Advanced AI Chips
- Nov 17Apple Smart Glasses Said to Debut at WWDC 2027 With No Display, Leaning on Siri and iPhone
- Nov 17AI Labs Race to Hire Counterintelligence Staff: Anthropic 33 This Year, OpenAI 22
™